For example, in vitro studies have demonstrated that tankyrase inhibitors can potentiate colorectal tumour cell responses to PI3-Kinase/AKT pathway inhibitors18 or MAP-kinase pathway (MEK) inhibitors19, suggesting that additional combination approaches involving tankyrase inhibitors might be of some value. The gene discussed is TNKS; the disease is colorectal neoplasm.